BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holko P, Kawalec P, Mossakowska M, Pilc A. Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland. PLoS One. 2016;11:e0168586. [PMID: 27992531 DOI: 10.1371/journal.pone.0168586] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Gong SS, Fan YH, Lv B, Zhang MQ, Xu Y, Zhao J. Fatigue in patients with inflammatory bowel disease in Eastern China. World J Gastroenterol 2021; 27(11): 1076-1089 [PMID: 33776374 DOI: 10.3748/wjg.v27.i11.1076] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A, Karlsson L. Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Eff Resour Alloc 2018;16:28. [PMID: 30123097 DOI: 10.1186/s12962-018-0114-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Everhov ÅH, Khalili H, Askling J, Myrelid P, Ludvigsson JF, Halfvarson J, Nordenvall C, Söderling J, Olén O, Neovius M. Sick Leave and Disability Pension in Prevalent Patients With Crohn's Disease. J Crohns Colitis 2018;12:1418-28. [PMID: 30165593 DOI: 10.1093/ecco-jcc/jjy123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
4 Holko P, Kawalec P, Mossakowska M. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. European Journal of Gastroenterology & Hepatology 2018;30:174-80. [DOI: 10.1097/meg.0000000000001031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
5 Baji P, Golicki D, Prevolnik-Rupel V, Brouwer WBF, Zrubka Z, Gulácsi L, Péntek M. The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. Eur J Health Econ 2019;20:5-16. [PMID: 31089990 DOI: 10.1007/s10198-019-01058-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
6 Parra RS, Chebli JM, Amarante HM, Flores C, Parente JM, Ramos O, Fernandes M, Rocha JJ, Feitosa MR, Feres O, Scotton AS, Nones RB, Lima MM, Zaltman C, Goncalves CD, Guimaraes IM, Santana GO, Sassaki LY, Hossne RS, Bafutto M, Junior RL, Faria MA, Miszputen SJ, Gomes TN, Catapani WR, Faria AA, Souza SC, Caratin RF, Senra JT, Ferrari ML. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol 2019; 25(38): 5862-5882 [PMID: 31636478 DOI: 10.3748/wjg.v25.i38.5862] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
7 van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther 2021;54:234-48. [PMID: 34114667 DOI: 10.1111/apt.16445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Pharmacoeconomics 2018;36:853-65. [PMID: 29667146 DOI: 10.1007/s40273-018-0653-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
9 Edwards SJ, Barton S, Bacelar M, Karner C, Cain P, Wakefield V, Marceniuk G. Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. Health Technol Assess 2021;25:1-138. [PMID: 33783345 DOI: 10.3310/hta25230] [Reference Citation Analysis]
10 Ruf B, Jenkinson P, Armour D, Fraser M, Watson AJ. Videoconference clinics improve efficiency of inflammatory bowel disease care in a remote and rural setting. J Telemed Telecare 2020;26:545-51. [PMID: 31167590 DOI: 10.1177/1357633X19849280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Hindryckx P, Laukens D, D'Amico F, Danese S. Unmet Needs in IBD: the Case of Fatigue. Clin Rev Allergy Immunol. 2018;55:368-378. [PMID: 28852978 DOI: 10.1007/s12016-017-8641-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
12 Parra RS, Feitosa MR, Ribeiro LCH, Castro LA, Rocha JJR, Féres O. Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy. Gastroenterol Res Pract 2018;2018:1952086. [PMID: 29853857 DOI: 10.1155/2018/1952086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]